Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Plain-language summary
This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 7 US locations across multiple states.
Who can join (key eligibility)
- Age 12 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
AZD3470 (DRUG): AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5. | Pembrolizumab (DRUG): Pembrolizumab (CAS nr: 1374853-91-4 )
- Drugs / treatments
- AZD3470, Pembrolizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details